Introduction: Endovenous thermal ablation (EVTA) stands as one of the primary treatments for superficial venous insufficiency. Concern exists about the potential for thromboembolic complications following this procedure. Although rare, those complications can be severe, necessitating early identification of patients prone to increased thrombotic risks. This study aims to leverage AI-based algorithms to forecast patients' likelihood of developing deep vein thrombosis (DVT) within 30 days following EVTA. Materials and Methods: From 2007 to 2017, all patients who underwent EVTA were identified using the American College of Surgeons National Surgical Quality Improvement Program database. We developed and validated 4 machine learning models using demographics, comorbidities, and laboratory values to predict the risk of postoperative deep vein thrombosis: Classification and Regression Trees (CART), Optimal Classification Trees (OCT), Random Forests, and Extreme Gradient Boosting (XGBoost). The models were trained using all the available variables. SHAP analysis was adopted to interpret model outcomes and offer medical insights into feature importance and interactions. Results: A total of 21,549 patients were included (mean age of 54 +- SD years, 67% female). In this cohort, 1.59% developed DVT. The XGBoost model had good discriminative power for predicting DVT risk with AUC of 0.711 in the hold-out test set for all-variable model. Stratification of the test set by age, BMI, preoperative white blood cell and platelet count shows that the model performs equally well across these groups. Conclusion: We developed and validated an interpretable model that enables physicians to predict which patients with superficial venous insufficiency has higher risk of developing deep vein thrombosis within 30 days following endovenous thermal ablation.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical standards were upheld throughout the study and approved by the institutional review board of Massachusetts General Hospital. A waiver of consent was obtained from the institutional review board committee due to the use of de-identified patient data and no identifiable medical risk, relying solely on pre-existing information in patient medical records.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes